reported April 30, 2009
This morning at the American Academy of Neurology’s conference in Seattle, a report was released reporting that there is a significantly increased risk of leukemia from the drug mitoxantrone (Novantrone) in patients with progressive forms of multiple sclerosis (MS).
Novantrone has always had significant health risks. When patients receive a dosage increase they must undergo regular cardiac monitoring due to the risk of cardiotoxicity and the threat of permanent heart damage.
continue reading this story by clicking here